Denosumab Clinical Trials

4 actively recruiting trials across 2 locations

Pipeline

Phase 2: 1Phase 1/2: 2

Top Sponsors

Washington University School of Medicine1
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
Shanghai Pulmonary Hospital, Shanghai, China1
City of Hope Medical Center1

Indications

Cancer2
Type 1 Diabetes1
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer1
Knee Osteoarthritis1
Arthritis1

Other2 trials

An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

Phase 2

Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis

Birmingham, Alabama1 trial

Denosumab for Type 1 Diabetes

University of Alabama at Birmingham

Phase 1/2

Westwood, Kansas1 trial

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

The University of Kansas Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.